The molecular patterns of resistance to anti-tuberculosis drugs: an analysis from Istanbul, Turkey

References

• Global tuberculosis report 2018. Geneva: World Health Organization; 2018.
   Google Scholar
• VSD raporu Türkiye’de Verem Savaş 2018 Raporu, T.C. Sağlık Bakanlığı. Ankara, 2018. https://hsgm.saglik.gov.tr/depo/birimler/tuberkuloz_db/dosya/raporlar/Tu_rkiye_de_Verem_Savas_2018_Raporu_kapakl_.pdf
   Google Scholar
• Global Tuberculosis Report. 2017. World Health Organization; 2016.
   Google Scholar
• Global Tuberculosis Report. 2017. World Health Organization; 2017.
   Google Scholar
• Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. Jun 2012;56:3271–3276.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, et al. Molecular detection of mutations associated with first and second-line drug resistance compared with conventional drug susceptibility testing in M. tuberculosis. Antimicrob Agents Chemother. 2011;55:2032–2041.
   PubMed Web of Science ®Google Scholar
• Yazisiz H, Cenger DH, Yazisiz V, Kılıç L, Altın S. Comparison and evaluation of Lowenstein-Jensen medium, Mycobacteria growth indicator tube 960, and microscopic smear results in the diagnosis of tuberculosis: a large data analysis from a single center. Clin Lab. 2019;65:2111–2117.
   Google Scholar
• Agarwal A, Katoch CDS, Kumar M, Dhole TN, Sharma YK. Evaluation of Microscopic observation drug susceptibility (MODS) assay as a rapid, sensitive and inexpensive test for detection of tuberculosis and multidrug resistant tuberculosis. Med J Armed Forces India. Jan 2019;75:58–64.
   PubMedGoogle Scholar
• Implementing tuberculosis diagnostics: A policy framework, WHO 2010. https://www.who.int/tb/publications/implementing_TB_diagnostics/en/
   Google Scholar
• Huang WL, Chen HY, Kuo YM, Jou R. Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug‐resistant Mycobacterium tuberculosis. J Clin Microbiol. 2009;47:2520–2524.
   PubMed Web of Science ®Google Scholar
• Bai Y, Wang Y, Shao C, Hao Y, Jin Y. GenoType MTBDRplus assay for rapid detection of multidrug resistance in Mycobacterium tuberculosis: A meta‐analysis. PLoS One. 2016;11:e0150321.
   PubMedGoogle Scholar
• Feng Y, Liu S, Wang Q, Wang L, Tang S, Wang J, et al. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: A meta‐analysis. PLoS One. 2013;8:e55292.
   PubMed Web of Science ®Google Scholar
• Mao X, Ke Z, Shi X, Liu S, Tang B, Wang J, et al. Diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol with genotype MTBDRsl assay: A meta‐analysis. Ann Clin Lab Sci. 2015;45:533–544.
   PubMed Web of Science ®Google Scholar
• Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, et al. Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance. N Engl J Med. Sep 2016; 375:1081–1089.
   PubMed Web of Science ®Google Scholar
• Global Tuberculosis Report. 2012. World Health Organization; 2012.
   Google Scholar
• Sezen F, Albayrak N, Özkara Ş, Karagöz A, Alp A, Duyar Ağca F, et al. Tüberküloz Laboratuvar Sürveyans Ağı Tulsa Çalışma Grubu, Tulsa. [Tuberculosis Laboratory Surveillance Network (TuLSA) study group. The first step for national tuberculosis laboratory surveillance: Ankara, 2011]. Mikrobiyol Bul. Apr 2015;49:143–155.
   PubMed Web of Science ®Google Scholar
• RüSch-Gerdes S, Domehl C, Nardi G, Gismondo MR, Welscher H-M, Pfyffer GE. Multicenter evaluation of the mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs. J Clin Microbiol. Jan 1999;37:45–48.
   PubMed Web of Science ®Google Scholar
• Hain Life Sciences. https://www.hain-lifescience.de/en/downloads/microbiology.html. (Accessed 18 Aug 2019).
   Google Scholar
• Gordis L. Epidemiology. 5th ed. Philadelphia: Saunders; 2013.
   Google Scholar
• Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J. Jan 2017;49:1601075.
   PubMed Web of Science ®Google Scholar
• Rigouts L, Hoza AS, De Rijk P, Torrea G, Chonde TM, Basra D, et al. Evaluation of the Genotype MTBDRplus assay as a tool for drug resistance surveys. Int J Tuberc Lung Dis. . 2011;15(7):959–965.
   PubMed Web of Science ®Google Scholar
• Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, Sanne I, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. Jul 2011;8:e1001061.
   PubMed Web of Science ®Google Scholar
• Chryssanthou E, Angeby K. The GenoType MTBDRplus assay for detection of drug resistance in Mycobacterium tuberculosis in Sweden. APMIS. May 2012;120:405–409.
   PubMed Web of Science ®Google Scholar
• Palomino JC, Martin A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel). Jul 2014;3:317–340.
   PubMedGoogle Scholar
• Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. Jul 2011;66:1417–1430.
   PubMed Web of Science ®Google Scholar
• de Steenwinkel JE, ten Kate MT, de Knegt GJ, Kremer K, Aarnoutse RE, Boeree MJ, et al. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB. Emerg Infect Dis. Apr 2012;18:660–663. 26
   PubMed Web of Science ®Google Scholar
• Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother. May 2018;73:1138–1151.
   PubMed Web of Science ®Google Scholar
• Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. Feb 2017;17:223–234.
   PubMed Web of Science ®Google Scholar
• Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res. 2001;2:164–168.
   PubMed Web of Science ®Google Scholar
• Caws M, Duy PM, Tho DQ, Lan NT, Hoa DV, Farrar J. Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J Clin Microbiol. Jul 2006;44:2333–2337. PubMed PMID:16825345
   PubMedGoogle Scholar
• Yadav RN, Singh BK, Sharma SK, Sharma R, Soneja M, Sreenivas V, et al. Comparative evaluation of GenoType MTBDR plus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR‐TB) at a tertiary care centre in India. PLoS One. 2013;8:e72036. pone.0072036.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li GL, Chen C, Wang JM, Martinez L, Lu W, et al. Diagnostic Performance of the GenoType MTBDRplus and MTBDRsl Assays to Identify Tuberculosis Drug Resistance in Eastern China. Chin Med J (Engl). Jul 2017;130:1521–1528.
   PubMed Web of Science ®Google Scholar
• Seifert M, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, et al. MTBDRplus and MTBDRsl Assays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis. J Clin Microbiol. Apr 2016;54:912–918.
   PubMed Web of Science ®Google Scholar
• Manson AL, Cohen KA, Abeel T, Desjardins CA, Armstrong DT, Barry CE, 3rd, et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nat Genet. 2017;49:395–402. Mar
   PubMed Web of Science ®Google Scholar
• Bergval I, Kwok B, Schuitema A, Kremer K, van Soolingen D, Klatser P, et al. Pre-existing isoniazid resistance, but not the genotype of Mycobacterium tuberculosis drives rifampicin resistance codon preference in vitro. PLoS One. 2012;7:e29108.
   PubMed Web of Science ®Google Scholar
• Gardee Y, Dreyer AW, Koornhof HJ, Omar SV, da Silva P, Bhyat Z, et al. Evaluation of the GenoType MTBDRsl version 2.0 assay for second-line drug resistance detection of Mycobacterium tuberculosis isolates in South Africa. J Clin Microbiol. 2017;55:791–800.
   PubMed Web of Science ®Google Scholar
• Maningi NE, Malinga LA, Antiabong JF, Lekalakala RM, Mbelle NM. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa. BMC Infect Dis. Dec 2017;17:795.
   PubMed Web of Science ®Google Scholar
• Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjo M, et al. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. J Clin Microbiol. 2015;53:2961–2969.
   PubMed Web of Science ®Google Scholar
• Tekin K, Albay A, Simsek H, Sig AK, Guney M. Evaluation of the BACTEC MGIT 960 SL DST Kit and the GenoType MTBDRsl Test for Detecting Extensively Drugresistant Tuberculosis Cases. Eurasian J Med. 2017;49:183–187.
   PubMed Web of Science ®Google Scholar
• Banu S, Rahman SM, Khan MS, Ferdous SS, Ahmed S, Gratz J, et al. Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory. J Clin Microbiol. Jan 2014;52:156–163.
   PubMedGoogle Scholar
• Zeng X, Jing W, Zhang Y, Duan H, Huang H, Chu N. Performance of the MTBDRsl Line probe assay for rapid detection of resistance to second-line anti-tuberculosis drugs and ethambutol in China. Diagn Microbiol Infect Dis. Oct 2017;89:112–117.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Sundaramurthi JC, Palaniappan AN, Narayanan S. Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis. Tuberculosis (Edinb). Dec 2016;101:31–40.
   PubMed Web of Science ®Google Scholar
• Safi H, Lingaraju S, Amin A, Kim S, Jones M, Holmes M, et al. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes. Nat Genet. Oct 2013;45:1190–1197.
   PubMed Web of Science ®Google Scholar